"Life-saving medicine" is close to the people, and the monthly average monthly minimum maintenance treatment for ovarian cancer in Guangzhou is less than 800 yuan

Since January 1, the new version of the National Medical Insurance Drug List has been officially implemented nationwide.
Many innovative tumor drugs and special drugs have been included in the medical insurance list, and have entered the fast-track price reduction, making life-saving drugs more accessible to the people
.
Sun Yat-Sen University Zhang Bingzhong, director of the Department of Gynecologic Oncology at Sun Yat-sen Memorial Hospital, said in an interview recently that the indications for first-line maintenance therapy of niraparib for ovarian cancer have been included in medical insurance reimbursement, which has benefited more patients
.
Li, for example, after the platinum-sensitive recurrence maintenance treatment was included in the medical insurance last year, this time its use in the first-line maintenance treatment of ovarian cancer for the whole population (regardless of the patient’s biomarker status) has also been expanded into the national medical insurance reimbursement scope, from the time of listing.
At the beginning of 25,000 yuan a box, after two medical insurance price cuts, the price has dropped to 4,584 yuan a box, plus medical insurance reimbursement, Guangzhou local patients only need to pay less than 800 yuan per month, which is 20,000 less than before medical insurance.
Yu Yuan
.
"Before the initial listing on the mainland, we had patients who had to go to Hong Kong to buy medicines, which cost 50,000 to 60,000 yuan a month.
Later, when the mainland was listed but there was no medical insurance coverage, the patient needed 25,000 yuan a month.
, the burden is indeed very heavy
.
Zhang Bingzhong said that the indications for the first-line maintenance treatment of niraparib for ovarian cancer have been included in medical insurance reimbursement, which means that all newly diagnosed ovarian cancer patients can receive niraparib maintenance treatment through medical insurance reimbursement
.
Ovarian malignant tumor is one of the common tumors in the female genitalia
.
Ovarian cancer is difficult to diagnose at an early stage, and it is a "silent killer" that threatens women's health
.
Compared with other tumors, the ovaries are located deep in the pelvic cavity of women's bodies and are very large in size.
Small," when it grows slowly, the patient doesn't feel it
.
Only when it grows to a certain extent, say the tumor is very large, or spreads to the pelvic abdominal organs, and thus produces a large amount of ascites, the patient will feel it
.
Zhang Bingzhong said that early ovarian cancer symptoms are not obvious, which makes it difficult to detect the disease in time, which delays treatment.

.
For a long time, clinicians and ovarian cancer patients have been troubled by three 70% clinical cases: about 70% of newly diagnosed patients are in advanced clinical stage; although the remission rate of first-line treatment with surgery combined with platinum-containing chemotherapy can reach more than 80%, 70% of ovarian cancer patients Cancer patients recur within two or three years after initial treatment; 70% of patients survive for no more than five years
.
"The mortality rate of ovarian cancer is relatively high, and the treatment effect is not satisfactory
.
" Zhang Bingzhong explained, "We found that only 30% of ovarian cancer patients can only live for more than 5 years, and it will recur after a period of time, so the total In recent years, with the
advent of molecularly targeted drugs for ovarian cancer, PARP inhibitors, as well as the publication of more and more high-quality high-level research results at home and abroad and evidence-based medical evidence Accumulation, niraparib and other PARP inhibitors have given ovarian cancer patients more hope for survival, and their clinical value in bringing significant long-term survival benefits to patients in ovarian cancer maintenance therapy has been confirmed
.
"After a patient takes medication, it takes 4 years to relapse
.
" Zhang Bingzhong pointed out: "At present, maintenance therapy has become an indispensable and important part of the whole management of ovarian cancer, and the treatment pattern of ovarian cancer has changed from treatment concept to clinical practice.
, has entered the standard mode of "surgery + chemotherapy + maintenance therapy", making long-term remission possible, which is a huge progress
.
" "For ovarian cancer patients, early treatment is beneficial, especially for newly diagnosed ovarian cancer patients.
For cancer patients, striving for the first treatment has a decisive impact on the survival period and quality of life of the patients
.
" Zhang Bingzhong concluded, "I believe that with the improvement of the availability of innovative drugs brought about by the medical insurance policy, it can be said that more ovarian cancer Patients can use new and good drugs as soon as possible, prolong life, delay recurrence, and achieve long-term standardized treatment
.
” (End)